  The Coronavirus Disease 2019 (COVID-19) pandemic has infected over 10 million
people globally with a relatively high mortality rate. There are many
therapeutics undergoing clinical trials, but there is no effective vaccine or
therapy for treatment thus far. After affected by the Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2), molecular signaling of host cells plays
critical roles during the life cycle of SARS-CoV-2. Thus, it is significant to
identify the involved molecular signaling pathways within the host cells, and
drugs targeting these molecular signaling pathways could be potentially
effective for COVID-19 treatment. In this study, we aimed to identify these
potential molecular signaling pathways, and repurpose existing drugs as a
potentially effective treatment of COVID-19 to facilitate the therapeutic
discovery, based on the transcriptional response of host cells. We first
identified dysfunctional signaling pathways associated with the infection
caused SARS-CoV-2 in human lung epithelial cells through analysis of the
altered gene expression profiles. In addition to the signaling pathway
analysis, the activated gene ontologies (GOs) and super gene ontologies were
identified. Signaling pathways and GOs such as MAPK, JNK, STAT, ERK, JAK-STAT,
IRF7-NFkB signaling, and MYD88/CXCR6 immune signaling were particularly
identified. Based on the identified signaling pathways and GOs, a set of
potentially effective drugs were repurposed by integrating the drug-target and
reverse gene expression data resources. The dexamethasone was top-ranked in the
prediction, which was the first reported drug to be able to significantly
reduce the death rate of COVID-19 patients receiving respiratory support. The
results can be helpful to understand the associated molecular signaling
pathways within host cells, and facilitate the discovery of effective drugs for
COVID-19 treatment.
